Ganglioside GD2 is specifically expressed in small-cell lung cancer (SCLC) cells, leading to enhancement of malignant phenotypes, such as cell proliferation and migration. However, how GD2 promotes malignant phenotypes in SCLC cells is not well known. In this study, to reveal the mechanisms by which GD2 increases malignant phenotypes in SCLC cells, we used enzyme-mediated activation of radical sources combined with mass spectrometry in GD2 + SCLC cells. Consequently, we identified ASC amino acid transporter 2 (ASCT2), a major glutamine transporter, which coordinately works with GD2. We showed that ASCT2 was highly expressed in glycolipidenriched microdomain/rafts in GD2 + SCLC cells, and colocalized with GD2 in both proximity ligation assay and immunocytostaining, and bound with GD2 in immunoprecipitation/TLC immunostaining. Malignant phenotypes of GD2 + SCLC cells were enhanced by glutamine uptake, and were suppressed by L-c-glutamyl-p-nitroanilide, a specific inhibitor of ASCT2, through reduced phosphorylation of p70 S6K1 and S6. These results suggested that ASCT2 enhances glutamine uptake in glycolipidenriched microdomain/rafts in GD2 + SCLC cells, leading to the enhancement of cell proliferation and migration through increased phosphorylation of the mTOR complex 1 signaling axis.
disease. 5 Previous studies reported that GD2 enhances malignant phenotypes such as cell proliferation and invasion activity, and anti-GD2 mAb induces apoptosis in SCLC cells. 3, 4 However, it is not well known how GD2 promotes malignant phenotypes in SCLC cells.
ASC amino acid transporter 2 (SLC1A5) 6, 7 is a major glutamine transporter that is highly expressed in several tumors, such as non-SLCL, clear cell renal cell carcinoma, triple-negative breast cancer, and neuroblastoma cells. [8] [9] [10] [11] [12] In triple-negative breast cancer cells, cell proliferation is increased by glutamine uptake by ASCT2, and the malignant phenotypes were decreased by GPNA, which specifically inhibits glutamine uptake by ASCT2. 11 Moreover, the growth of NSCLC cells injected into the flank of nude mice was significantly suppressed by GPNA. 13 Mammalian target of rapamycin complex 1 is deeply associated with malignant phenotypes of cancer cells. The loss of p53, a very common event in cancer, promotes activation of mTORC1 and malignant phenotypes. 14, 15 Recently, it was reported that glutamine is a key amino acid to activate mTORC1 through Arf1 in lysosome lumen. 16, 17 A downstream factor of mTORC1, p70 S6K1, is dephosphorylated by inhibiting glutamine uptake in triple-negative breast cancer cells. 11 Moreover, glutamine uptake by ASCT2 is also required for the activation of mTORC1 for T-cell differentiation. 18 Although roles of GD2 in malignant phenotypes of SCLC have been analyzed, there is no information about molecules interacting with GD2 in GEM/rafts. To date, it has been reported that GD3
interacts with membrane proteins in melanomas and glioma cells, which promotes malignant phenotypes of individual cancer cells. 19, 20 In this study, we aimed to reveal the molecular mechanisms by which GD2 expressed on the membrane of SCLC cells induces malignant phenotypes, then used EMARS combined with MS 21, 22 to address this aim. By EMARS combined with MS analysis, we identified molecules associating with GD2 in GEM/rafts of SCLC cells, and analyzed the interaction between GD2 and these target molecules.
Consequently, we identified ASCT2 as a molecule associating with GD2 in SCLC cells. Here, we show the roles of ASCT2 in GD2 + SCLC cells, and the mechanisms by which GD2 and ASCT2 co-operate in the enhancement of malignant phenotypes of SCLC cells.
| MATERIALS AND METHODS

| Cell culture
D-8, D-13, and D-18 were SK-LC-17 transfected with GD3 synthase cDNA, and C-2, C-6, and C-8 were SK-LC-17 transfected with a control vector. 3, 23 Human a-2,8-sialyltransferase (GD3 synthase) cDNA clone pD3T-31 was subcloned into pMIKneo vector (Assoc.
Prof. Kazuo Maruyama, Dep. Hygiene, Tokyo Medical Dental University, Tokyo, Japan) to obtain the pMIKneo/D3T-31. 23 SK-LC-17 cell lines used for cDNA transfection were plated on a 60-mm plastic tissue culture plate at a density of 6 9 10 5 cells/4 mL/plate. After 24 hours, the medium was removed and the cells were washed twice with serum-free DMEM. The pMIKneo/D3T-31 vector (4 lg)
was mixed with Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA), then added to the cells in the plate. After 6 hours of incubation, the medium was changed to the regular one as described above. Stable transfectants were selected with 250 lg/ mL G418. Other SCLC cell lines, NCI-N417 and ACC-LC-171, were described previously. 3 These cell lines were cultured in RPMI-1640 supplemented with 10% FCS and G418 (250 lg/mL) at 37°C in a humidified atmosphere containing 5% CO 2 .
| Construction and transfection of expression vectors
GD3 synthase cDNA was previously described. 23 The cDNA of human ASCT2 was subcloned into pCMV- Tag 
| Antibodies and reagents
Mouse anti-GD3 mAb (R-24) was obtained from Dr. L.J. Old (Memorial Sloan Kettering Cancer Center, New York, NY, USA). Mouse anti-GD2 mAb (220-51) was generated in our laboratory. Rabbit anti-flotillin-1
antibody, rabbit anti-caveolin-1 antibody, mouse anti-CD109 mAb, rabbit anti-PDGFRa antibody, goat anti-ASCT2 antibody, and mouse anti-c-myc antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-ASCT2 antibody, rabbit anti-phospho-mTOR antibody (Ser2448), rabbit anti-mTOR mAb, mouse antiphospho-p70 S6 kinase mAb (Thr389), rabbit anti-p70 S6 kinase mAb, rabbit anti-S6 ribosomal protein mAb, rabbit anti-phospho-S6 ribosomal protein mAb (Ser235/Ser236), rabbit anti-EphA2 mAb, and rabbit anti-CD44 antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Goat anti-urokinase plasminogen activator surface receptor antibody was purchased from R&D Systems (Minneapolis, MN, USA). Rabbit anti-c-myc antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit anti-ASCT2 conjugated with Alexa 488 was purchased from Bioss (Woburn, MA, USA).
| Flow cytometry
Surface expression of ganglioside GD2, GD3, and ASCT2 on SK-LC- IgG antibody for 45 minutes. After washing with PBS, relative expression levels of GD2, GD3, and ASCT2 were analyzed by FACSCalibur.
| Enzyme-mediated activation of radical sources and MS analysis
The EMARS reactions and MS analysis were carried out as described previously. 21 2.10 | Sucrose density gradient fractionation of
Briji35 extracts
Sucrose density gradient fractionation was carried out as reported previously with modification. 24 Briefly, cells (1.0 9 10 7 ) were lysed by MES + NaCl + EDTA (MNE) buffer containing 1% Briji35. After removing insoluble materials by centrifugation at 14 000 g for 10 minutes, lysates were dounced 10 times with a Digital Homogenizer (As One, Osaka, Japan). The lysates were mixed with an equal
volume of 80% sucrose in MNE buffer, and stepwise gradient was prepared by overlaying 30% sucrose in MNE buffer followed by a final layer of 5% sucrose in MNE buffer. The gradient was formed by centrifugation for 14-16 hours at 4°C at 100 000 g using an MLS50 rotor (Beckman Coulter, Brea, CA, USA). Fractions of 500 lL were separated from the top of the gradient and were used for Western blot analyses. Germany).
|
| Proximity ligation assay
Proximity ligation assay was carried out using a Duolink in situ PLA kit (Sigma-Aldrich), following the manufacturer's protocol.
Briefly, cells (2 9 10 5 ) were plated on a glass-bottomed dish 
| In vitro migration assay
The confluent cells were scratched with a 1000-lL disposable plastic Figures 1A, S1 ). C-2, C-6, and C-8 are GD2 À SK-LC-17 transfectants (Figures 1A, S1 ). Tumor-specific gangliosides coordinately work with plasma membrane proteins in cancer cells, which leads to enhancement of malignant phenotypes. Figure 1B) . In this method, molecules located within a 100-200-nm diameter of GD2 were labeled with FITC by radical reaction of an aryl azide functional group. 21, 22 Then FITC-labeled molecules were collected by immunoprecipitation using an anti-FITC antibody ( Figure 1C ). These EMARS-IP samples were applied to liquid chromatography-MS/MS analyses to identify the labeled molecules. We succeeded in identifying 15 plasma membrane proteins as GD2-associating molecules in D-13 and D-18 ( Figure 1D , Table 1 ).
Among the common GD2-associating molecules between D-13 and because the scores of these molecules were high (protein identification probabilities were more than 99%), and they were classified into membrane molecules.
3.2 | ASC amino acid transporter 2 associated with GD2 in GEM/rafts Next, we examined which candidate molecules more specifically work with GD2 in SCLC cells. Gangliosides are mainly expressed on the plasma membrane and localized in GEM/rafts, 1,2 and we predicted that these five candidate molecules are highly expressed in GEM/rafts. Therefore, we fractionated detergent extracts from SK-LC-17 transfectants by sucrose density-gradient ultracentrifugation, 24 and analyzed levels of ASCT2, CD109, urokinase plasminogen activator surface receptor, CD44, and EphA2 expression in the raft fractions of SK-LC-17 transfectants (Figure 2A ). Interestingly, ASCT2 was highly expressed in GEM/rafts of GD2 + SK-LC-17 transfectants, whereas it was only minimally detected in GEM/rafts of GD2 À SK-LC-17 transfectants (Figures 2A, S2 ). The expression level of EphA2 in the raft fractions of GD2 + SK-LC-17 transfectants was also higher than in GD2 À SK-LC-17 transfectants (Figures 2A, S2) . Although EphA2 has emerged to be strongly associated with malignant phenotypes in glioma cells and lung cancer cells, 26, 27 the function of ASCT2 has been poorly understood in SCLC cells. Therefore, we focused on ASCT2, and studied the association between ASCT2 and GD2. We selected C-2, C-8, D-8, and D-13 clones, because expression levels of ASCT2 in GEM/rafts were very different among them. Surprisingly, total expression levels of ASCT2 in all SK-LC-17 transfectants were not considerably different ( Figure 2B ). In addition, expression levels of ASCT2 on the plasma membrane among SK-LC-17 transfectants were not largely different ( Figure S3 ).
Based on high expression of ASCT2 in GEM/rafts, we examined whether ASCT2 binds with GD2. We transfected c-myc-tag ASCT2 cDNA into GD2 + SK-LC-17 cells, and undertook immunoprecipitation and immunoblotting using anti-c-myc antibody and anti-ASCT2 antibody, respectively ( Figure 2C ). The IP products with anti-c-myc antibody were applied to TLC immunostaining to detect GD2. Consequently, we found that GD2 was co-precipitated with ASCT2 ( Figure 2D ), suggesting molecular complex formation of ASCT2 and GD2. In IP-TLC immunostaining, background was sometimes high, and faint bands were detected in IP with the normal IgG lane if we want to show definite bands of GD2 in ASCT2 precipitates ( Figure 2D ). In turn, GD3 was not co-precipitated with ASCT2 ( Figure S4 ). We tried to further confirm that GD2 was co-precipitated with ASCT2 in other SCLC cells, NCI-N417 and ACC-LC-171 expressing endogenous GD2 ( Figure S5A ).
We undertook IP-TLC immunostaining ( Figure S5B,C) . Unfortunately, we did not find that GD2 was co-precipitated with ASCT2, probably due to poor transfection efficiency ( Figure S5B,C) . Next, to reveal whether ASCT2 was really a specific molecule to GD2, we examined whether a membrane protein binds with GD2. Previously, we reported that PDGFRa was identified as a molecule associating with GD3 by EMARS-MS, and interacts with GD3 in T A B L E 1 Candidate molecules associating with ganglioside GD2 as defined in enzyme-mediated activation of radical sources-mass spectrometry M.W., molecular weight. We considered that scores (probabilities) of the molecules were >50, and common candidate molecules associating with GD2 between D-13 and D-18 are shown.
glioma cells. 19 In SK-LC-17 transfectants, PDGFRa was expressed in the non-raft fraction (Figure 2A) , and GD2 was not co-precipitated with PDGFRa ( Figure S6 ). Taking these results together, ASCT2 is specifically expressed in GEM/rafts of GD2 + SK-LC-17
transfectants, and associated with GD2, thereby promoting malignant phenotypes.
| Colocalization of ASCT2 with GD2 in GEM/rafts
Next, we undertook immunofluorescence/double staining to examine whether ASCT2 is colocalized with GD2. c-Myc-tag ASCT2 derived from transfected cDNA was detected in a restricted portion of the cytoplasm F I G U R E 2 ASC amino acid transporter 2 (ASCT2) associated with ganglioside GD2 in glycolipid-enriched microdomain (GEM)/rafts. A, Fractionation of 1% Briji35 extracts from GD2 + SK-LC-17 transfectants was carried out by sucrose density gradient ultracentrifugation. Cells (1.0 9 10 7 ) were lysed by MES + NaCl + EDTA (MNE) buffer containing 1% Briji35. The lysates were mixed with an equal volume of 80% sucrose in MNE buffer, and stepwise gradient was prepared by overlaying 30% sucrose in MNE buffer followed by a final layer of 5% sucrose in MNE buffer. The gradient was formed by ultracentrifugation for 14-16 h at 4°C at 100 000 g. Fractions of 500 lL were separated from the top of the gradient and used for Western blotting. Caveolin-1 and flotillin-1 are GEM/raft markers. B, Total expression levels of ASCT2 were analyzed by Western blotting using an anti-ASCT2 antibody (left panel). N-linked glycosylation was deleted using N-glycosidase F. Expression levels of ASCT2 mRNA were analyzed by RT-quantitative PCR (right panel). Expression levels of ASCT2 mRNA were normalized by the GAPDH gene. C, Results of immunoprecipitation (IP)-immunoblotting (IB) experiments. Cells (1.0 9 10 6 ) were transfected with c-myc-tag ASCT2 cDNA and incubated for 48 h. Cells were lysed by lysis buffer containing 1% Triton X-100, and c-myc-tag ASCT2 was immunoprecipitated using an anti-c-myc antibody. Total cell lysate was used as input. D, After immunoprecipitation, thin-layer chromatography (TLC) immunostaining was undertaken using anti-GD2 mAb (220-51) to detect GD2. Bovine brain gangliosides (BBG, 1.0 lg) and pure GD2 (0.25 lg) were used as standards ESAKI ET AL.
| 147 and plasma membrane. It was colocalized with GD2 on the plasma membrane of GD2 + SK-LC-17 transfectants ( Figure 3A) . As for endogenous ASCT2, we found that it was also colocalized with GD2 ( Figure S7 ). As caveolin-1 is a GEM/raft marker, we examined whether c-myc-tag ASCT2 was colocalized with caveolin-1. As a result, we found that c-myctag ASCT2 was colocalized with caveolin-1 on the plasma membrane in GD2 + SK-LC-17 transfectants ( Figure 3B ). Although we described that GD2 was not precipitated with ASCT2 in other SCLC cell lines, NCI-N417 and ACC-LC-171 ( Figure S5B ,C), we found that GD2 was colocalized with both endogenous and exogenous ASCT2 ( Figure S8 ).
This result of the double immunofluorescence study was not enough to confirm a close association between GD2 and ASCT2.
Therefore, we undertook the PLA and showed a close association between them ( Figure S9 ). Moreover, GD2 and ASCT2 were also closely associated in NCI-N417 and ACC-LC-171 cells ( Figure S10 ). These data clearly showed that ASCT2 was colocalized with GD2 in GEM/ rafts in GD2 + SK-LC-17 transfectants, and suggested that ASCT2 was also closely associated with GD2 in NCI-N417 and ACC-LC-171 cells.
3.4 | Malignant phenotypes were suppressed by ASCT2 inhibitor GPNA ASC amino acid transporter 2 is a major glutamine transporter, and promotes malignant phenotypes in several cancer cells.
8-12
Therefore, we examined the level of glutamine uptake in SK-LC-17
transfectants. First, to measure the initial velocity of glutamine uptake in SK-LC-17 transfectants, we examined the time course of glutamine uptake in D-13. We found that glutamine uptake into D-8 occurred in a linear mode for the first 1 minute ( Figure S11 ). Next, we compared glutamine uptake among SK-LC-17 transfectants for the first 1 minute. Glutamine uptake was significantly different between GD2 + SK-LC-17 transfectants and GD2 À SK-LC-17 transfectants within initial linear phase, which suggested that initial velocities of glutamine uptake of GD2 + SK-LC-17 transfectants were higher than those of GD2 À SK-LC-17 transfectants ( Figure 4A ).
Next, we examined roles of glutamine in the malignant phenotypes
by using MTT assay to analyze cell proliferation. We found that cell proliferation was significantly increased in GD2 + SK-LC-17 transfectants in the presence of glutamine ( Figure 4B ). Cell proliferation was not detected without glutamine (data not shown).
To examine the function of ASCT2, we used GPNA, which specifically inhibits glutamine uptake by ASCT2. 11, 13 Glutamine uptake was significantly decreased in SK-LC-17 transfectants by GPNA ( Figure 4A ). To clarify whether glutamine uptake was really regulated by ASCT2 in SK-LC-17 transfectants, we examined glutamine uptake in SK-LC-17 transfectants treated with anti-ASCT2 siRNAs. We prepared three kinds of anti-ASCT2 siRNAs (#1, #2, and #3) and tested knockdown efficiency of ASCT2 in SK-KC-l7 ) were scratched and washed twice. After 16 h, migration rates (migration area at 16-0 h) were calculated. Scale bar = 100 lm. *P < .05; **P < .01; ***P < .001 These results suggested that glutamine uptake through ASCT2
leads to the activation of the mTORC1 signaling axis that is involved, at least partly, in the enhancement of cell proliferation and migration in GD2 + SK-LC-17 cells.
| DISCUSSION
In order to develop novel treatments for cancer, it is essential to identify tumor-specific molecules. Ganglioside GD2 is specifically expressed in SCLC cells, but hardly expressed in NSCLC cells or normal tissues. 3 Previous studies reported that GD2 promoted malignant phenotypes, such as cell proliferation and invasion, and anti-GD2 mAb induced apoptosis in SCLC cells. 3, 4 However, it was not well known how GD2 works in SCLC cells. We addressed this issue focusing on SCLC in this study. Recently, it has been reported that the EMARS method is a novel way to identify molecules interacting with gangliosides. 21, 22 For example, PDGFRa was identified as a GD3-associating protein in glioma cells using the EMARS method. 19 Moreover, neogenine, a membrane protein that promotes the development of the nervous system, was identified as a GD3-associating molecule in melanoma cells. Neogenin enhanced malignant phenotypes in melanoma cells through its intracellular domain as a transcription factor. 20 In this study, we undertook EMARS and ) were incubated for 0, 12, 24, 36, and 48 h in RPMI-1640 containing 1 mmol/L L-c-glutamyl-p-nitroanilide (GPNA). B, Intensity of bands of phosphorylated mTOR, S6K1, and S6 was scanned; data are presented in graphs after correction with those of total mTOR, S6K1, and S6, respectively cell surface. Among the candidate molecules, ASCT2 was specifically expressed in GEM/rafts of GD2 + SK-LC-17 transfectants (Figure 2A) . Therefore, we identified ASCT2 as a representative molecule associating with GD2. Several transcription factors, such as activating transcription factor 4, N-myc, and E2F3, promoted glutamine metabolism through ASCT2 in several tumors, 12, 28, 29 and N-myc and E2F3 were highly expressed in SCLC cells. 30, 31 However, in this study, the total expression level of ASCT2 was not considerably different among SK-LC-17 transfectants ( Figure 2B ).
Hence, GD2 did not seem to affect ASCT2 expression in SK-LC-17 cells. ASC amino acid transporter 2 contains two putative N-linked glycosylation sites (N163 and N212), and ASCT2 is transported to the plasma membrane depending on N-linked glycosylation. 32 However, the expression levels of ASCT2 on the plasma membrane is the same among SK-LC-17 transfectants ( Figure S3 ). Taking membrane trafficking of ASCT2 and our results together, it might be true that GD2 does not recruit mature ASCT2 to the plasma membrane but to GEM/rafts. However, the trafficking mechanism of ASCT2 remains to be elucidated in detail. We found that GD2
bound with ASCT2 in GD2 + SK-LC-17 transfectants ( Figures 2C,D, S9), and GD2 was also closely associated with ASCT2 in NCI-N417
and ACC-LC-171 cells ( Figures S8, S10 ). Previously, it was reported that sialic acid-containing GM3 bound with insulin receptor through lysine residue on the plasma membrane, 33 indicating that a sialic acid of ganglioside binds with basic amino acids of membrane proteins. Interestingly, we found that three basic amino acids of ASCT2 located at the neighboring region of the plasma membrane, suggesting that GD2 might bind with ASCT2 through these three residues.
ASC amino acid transporter 2 is coexpressed with LAT1 (SLC7A5) in several tumors such as lung adenocarcinomas, leukemia, and tongue cancer, and the expression of both ASCT2 and LAT1 enhances malignant phenotypes of cancers in vitro and in vivo. [34] [35] [36] The mechanism by which the combination of ASCT2
and LAT1 increases malignant phenotypes in cancer cells is considered to be due to activation of the mTORC1 signaling pathway.
ASC amino acid transporter 2 and LAT1 are a major glutamine transporter and a major leucine transporter, respectively, and both of these amino acids activate the mTORC1 signaling pathway in an independent manner. 16 Although the interaction between ASCT2
and LAT1 is poorly understood in SCLC cells, both transporters might co-operate and activate the mTORC1 signaling axis. Our data and previous studies showed that glutamine uptake by ASCT2 activated the mTORC1 signaling axis, such as p70 S6K1 and S6. 37 Recent studies elucidated that p70 S6K1 regulates cell migration and invasion in cancer cells. [38] [39] [40] Moreover, p70 S6K1-mediated phosphorylation controls phosphatidylinositol 4-phosphate 5-kinase type I degradation to regulate development of focal adhesions and invadopodia, and consequently, cell migration and invasion. 41 In this study, GPNA decreased glutamine uptake by ASCT2 in SK-LC-17
transfectants, leading to inactivated signaling of p70 S6K1, and consequently to reduced cell migration ( Figures 4D, 5A,B) . These results suggest that glutamine regulates cell migration based on p70 S6K1-phosphatidylinositol 4-phosphate 5-kinase type I in SK-LC-17 transfectants.
ASC amino acid transporter 2 is considered to be a novel target for treatment in several tumors, [8] [9] [10] [11] [12] and several ASCT2 inhibitors have been developed. To examine whether anti-GD2 mAb enhances the effect of ASCT2 inhibitors, such as GPNA and BenSer, 42 in SCLC cells, we will perform dual administration of anti-GD2 mAb and GPNA in vitro and in vivo, in SCLC cells and a xenograft model, respectively. GD2 is also a promising target for treatment of neuroblastoma, and anti-GD2 mAb has been developed for therapy trials. 5, 43, 44 However, little is known about how GD2 promotes malignant phenotypes in neuroblastoma cells. It has been reported that ASCT2 is also expressed in neuroblastoma cells, and promotes malignant phenotypes by glutamine uptake. 12 GD2 might also interact with ASCT2 on the plasma membrane of neuroblastoma cells, leading to enhancement of malignant phenotypes. Recently, ADCs have been vigorously developed for oncology therapeutics. 45 Gangliosides including GD2 are adequate antigen targets for ADCs, because several gangliosides are specifically expressed in tumor cells.
Therefore, ADCs targeting gangliosides are thought to be effective therapeutics for tumors. The results of this study suggest that anti-GD2 mAb conjugated with an ASCT2 inhibitor is an effective strategy for novel therapy towards SCLC cells and neuroblastoma cells.
In conclusion, we uncovered the roles of GD2 in SCLC cells in this study. GD2 recruits ASCT2 to GEM/rafts and enhances glutamine uptake through ASCT2 in SCLC cells. As a result, malignant phenotypes, such as cell proliferation and migration, were increased through activation of the mTORC1 signaling axis.
